Evidence map›Paper›PMID 40847644›Full record

Trial reportThe Journal of dermatology2025

An Open-Label, Multicenter, Phase II Study of Bexarotene in Patients with Adult T-Cell Leukemia/Lymphoma.

Kentaro Yonekura, Ikko Muto, Motoi Takenaka, Jun Aoi, Taku Fujimura, Masahiro Amano, Takuro Kanekura, Takuya Miyagi, Kanami Saito, Eiji Kiyohara and 9 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kentaro YonekuraDepartment of Dermatology, Imamura General Hospital, Kagoshima, Japan.ORCID https://orcid.org/0000-0002-9030-247X
Ikko MutoDepartment of Dermatology, Kurume University, Kurume, Japan.
Motoi TakenakaDepartment of Dermatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.ORCID https://orcid.org/0000-0002-7045-2518
Jun AoiDepartment of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Taku FujimuraDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID https://orcid.org/0000-0001-6809-5833
Masahiro AmanoDepartment of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Takuro KanekuraDepartment of Dermatology, Kagoshima University School of Medicine, Kagoshima, Japan.
Takuya MiyagiDepartment of Dermatology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.ORCID https://orcid.org/0000-0003-0801-2770
Kanami SaitoDepartment of Dermatology, Faculty of Medicine, Oita University, Yufu, Japan.ORCID https://orcid.org/0009-0007-2310-3677
Eiji KiyoharaDepartment of Dermatology, Graduate School of Medicine, Osaka University, Suita, Japan.
Takatoshi ShimauchiDepartment of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.ORCID https://orcid.org/0000-0002-0369-869X
Ken WatanabeDepartment of Dermatology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan.
Tomoko MiyakeDepartment of Dermatology, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.ORCID https://orcid.org/0000-0002-2644-6380
Takamichi ItoDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hisashi UharaDepartment of Dermatology, Sapporo Medical University, Sapporo, Japan.ORCID https://orcid.org/0000-0001-5391-3397
Kazuyasu FujiiDepartment of Dermatology, Kagoshima University School of Medicine, Kagoshima, Japan.ORCID https://orcid.org/0000-0002-6482-8953
Akihito SudoMinophagen Pharmaceutical, Tokyo, Japan.
Toshiki WatanabeDepartment of Practical Management of Medical Information, Graduate School of Medicine, St Marianna University, Kawasaki, Japan.
Keiji IwatsukiDepartment of Dermatology, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A multicenter, open-label, historically controlled, 2-arm phase II study was conducted to evaluate the safety, efficacy, and pharmacokinetics of bexarotene in Japanese patients with adult T-cell lymphoma/leukemia (ATL). The study enrolled patients with indolent ATL and skin lesions and patients with aggressive ATL who had skin relapse after achieving remission following ≥ 1 regimen of systemic chemotherapy. Patients received oral bexarotene at an initial dose of 100 mg/m

Indexed as

BexaroteneLeukemia-Lymphoma, Adult T-CellSkin NeoplasmsTetrahydronaphthalenesAdministration, OralAdultAgedFemaleHumansJapanMaleMiddle AgedTreatment OutcomeBexaroteneTetrahydronaphthalenesadult T‐cell leukemia/lymphomabexaroteneretionidskin lesionsystemic therapy

Identifiers

PMID40847644
PMCPMC12592592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.